Building Defensible Compliance Around Retatrutide to Maximize Sale Price

One of the most practical steps practice owners can take to protect and potentially enhance practice value is building strong, defensible compliance systems around any new or investigational therapies. This is not just a risk management exercise — it is a value creation strategy.

Defensible compliance around a retatrutide program has four core components:

Clear policies. Written policies that define how the practice evaluates, approves, and manages investigational compound programs. These policies should specify who has authority to approve new programs, what documentation is required before a program begins, and how compliance is monitored on an ongoing basis.

Thorough documentation. Complete records for every aspect of the program — IRB protocol, consent forms, adverse event logs, supply chain records, staff training records. Documentation that is complete, organized, and accessible is the foundation of a defensible compliance position.

Appropriate structural separation. Where needed, structural separation between the research program and the standard clinical practice. This may include separate record-keeping systems, separate billing processes, and clear delineation of which patients are research subjects and which are standard clinical patients.

Consistent application. Compliance standards that are applied consistently across all patients, all staff, and all locations. Inconsistent application — where some patients get proper consent and others do not, or where some staff follow the protocol and others do not — is a compliance failure even if the written policies are excellent.

From experience exiting practices, buyers pay for clean, well-documented operations. Compliance discipline around emerging therapies is increasingly viewed as a marker of operational maturity rather than an afterthought.

When a practice can demonstrate that it has thoughtfully evaluated and structured access to new compounds, it signals strong leadership and lower risk to potential acquirers. The message to a buyer is: this practice knows how to manage clinical complexity without creating liability. That is a premium-worthy characteristic.

Conversely, practices that have taken a more casual approach to new agents often face increased scrutiny, lower offers, or requests for indemnification during due diligence. The cost of weak compliance can show up directly in the purchase price or deal structure — in the form of escrow holdbacks, earn-out provisions that shift risk to the seller, or outright price reductions.

The time to build compliance infrastructure is before you need it — not when a buyer's due diligence team is asking for documentation that does not exist. Compliance infrastructure built retroactively is less credible and less complete than infrastructure built from the beginning.

If you are running a retatrutide program without complete compliance documentation, the most important thing you can do right now is start building it. Work with healthcare counsel to assess what you have, identify the gaps, and develop a plan to address them. A program with incomplete documentation that is actively being remediated is in a better position than a program with incomplete documentation and no remediation plan.

The valuation impact of compliance infrastructure is not speculative. In the current M&A environment for weight loss and medical aesthetics practices, buyers are applying meaningful discounts to practices with compliance gaps around investigational compound programs. Those discounts can range from 5–15% of enterprise value — a significant number on a practice valued at $2–5 million.

The cost of building proper compliance infrastructure — healthcare counsel fees, IRB costs, documentation systems — is a fraction of the valuation discount it prevents. It is one of the highest-return investments a practice owner can make in the years leading up to an exit.